SEC Form 4 · accession 0001861477-26-000005
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth H.Z. Thompson
Officer — EVP, Head of Research & Dev
Period of report
Jul 29, 2026
Accepted (ET)
Jul 31, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 29, 2026 | M | 32,272 | — | A | 35,552 | D | |
| Common Stock | Jul 30, 2026 | S | 16,508 | $26.13 | D | 19,044 | D | |
| Common Stock | Jul 30, 2026 | S | 50 | $26.17 | D | 18,994 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jul 29, 2026 | M | 32,272 | D | — | — | Common Stock | 32,272 | 32,272 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- F350% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.